Alopecia areata is a chronic autoimmune disorder causing non-scarring hair loss due to immune system attacks on hair follicles. Breakdown of immune privilege in hair follicles leads to infiltration by ...

Editor’s note: This is a previously posted video, and the below is an automatically generated transcript to be used for informational purposes. Please notify editor@healio.com if there are concerns ...

In an interview with Brittany Craiglow, MD, FAAD, dermatologist at Dermatology Physicians of Connecticut in Fairfield, she advocates for combination therapies using baricitinib to treat pediatric ...

Eli Lilly and Company’s Olumiant (baricitinib) has been recommended for approval in Europe for adolescents with severe ...

Alopecia areata is a nonscarring hair-loss condition that often has a patchy distribution and can be quite unpredictable. Alopecia areata is believed to be an autoimmune disease [1] involving T ...

For Christian Daniels, it started when his co-worker pointed out a dime-sized bald patch on the back of his head. Within days, he was waking up each morning to find clumps of hair on his white ...

Just a year after the U.S. Food and Drug Administration (FDA) approved the first treatment for severe alopecia areata, the federal agency has approved a second treatment for the disfiguring skin ...

Alopecia areata is an autoimmune disorder that usually results in unpredictable, patchy hair loss. Approximately 7 million people in the U.S. have alopecia areata, and it can affect anyone of any age ...

Please provide your email address to receive an email when new articles are posted on . By week 152, 80% of patients who were withdrawn from baricitinib therapy lost their hair again vs. only 7% of ...

Nearly three-quarters of adults with alopecia areata (AA) were not receiving treatment 1 year after diagnosis, according to a retrospective cohort study using data from more than 45,000 individuals.